Cargando…
Impact of cause of death adjudication on the results of the European prostate cancer screening trial
BACKGROUND: The European Randomised Study of Prostate Cancer Screening has shown a 21% relative reduction in prostate cancer mortality at 13 years. The causes of death can be misattributed, particularly in elderly men with multiple comorbidities, and therefore accurate assessment of the underlying c...
Autores principales: | Walter, Stephen D, de Koning, Harry J, Hugosson, Jonas, Talala, Kirsi, Roobol, Monique J, Carlsson, Sigrid, Zappa, Marco, Nelen, Vera, Kwiatkowski, Maciej, Páez, Álvaro, Moss, Sue, Auvinen, Anssi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220145/ https://www.ncbi.nlm.nih.gov/pubmed/27855442 http://dx.doi.org/10.1038/bjc.2016.378 |
Ejemplares similares
-
Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022) -
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish
section of the ERSPC
por: Pashayan, Nora, et al.
Publicado: (2015) -
Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021) -
Editorial Comment: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
por: Hugosson, J, et al.
Publicado: (2020) -
Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)